Lymphoma: all 5,623 studies
Page 3 of 57. Open to participants first (823), then studies with results posted, then the rest; newest registration first within each.
- Study to Assess Effectiveness and Safety of Zanubrutinib for Patients with Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)RecruitingNCT06823960
- A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/Refractory B-cell Non-Hodgkin LymphomaRecruitingNCT06822868Phase 1
- Development of an Intervention Integrating Procedures Combining Hypnosis and Virtual Reality in the Support of Patients with Hematological CancerNot yet recruitingNCT06817759Not applicable
- Italian Study of Patients with LymphomaRecruitingNCT06814925
- Study to Assess Clinical Characteristics and Outcome of Patients with Marginal Zone LymphomasRecruitingNCT06806488
- Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological MalignanciesRecruitingNCT06801002Phase 1
- Immunotherapy in LymphomaRecruitingNCT06796517
- The Implementation of the Go Wish Game to Promote Advance Care Planning in Onco- Hematologic DiseaseRecruitingNCT06795815Not applicable
- Optimization of 18F-FDG PET/CT Response Assessment and Prognostic Evaluation Strategies for High-Metabolism LymphomaRecruitingNCT06795113
- A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing SettingRecruitingNCT06794268
- Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell LymphomaRecruitingNCT06793956Phase 1
- A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing SettingRecruitingNCT06788652
- A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing SettingRecruitingNCT06788639
- Mechanistic Study of EBV mRNA Vaccine (WGc-043) in EBV-Positive Relapsed/Refractory LymphomaNot yet recruitingNCT06788600
- An Italian Multicentric Retrospective Observational Study to Assess Effectiveness and Safety of the Combination of Tafasitamab and Lenalidomide in Diffuse Large B-cell Lymphoma Patients Treated Under Named Patient ProgramRecruitingNCT06782789
- Study in Patients with Relapsed/refractory Primary Mediastinal Lymphoma Treated with Pembrolizumab or Nivolumab in Combination with Brentuximab Vedotin in a Real-life ContextRecruitingNCT06781450
- Retrospective Observational Study of Italian Cohort of Lymphoma Patients (RETRO-LYMPH)RecruitingNCT06781437
- Role of Spectral CT in the Evaluation of Cardiotoxicity in Patients With Hodgkin's Lymphoma and Diffuse Large B-cell Lymphoma Treated With AnthracyclinesRecruitingNCT06774326
- CHiR Therapy for Elderly DLBCL Intolerant to ChemoRecruitingNCT06764017Phase 2
- BV in the Treatment of Relapsed/refractory Hodgkin LymphomaNot yet recruitingNCT06761911Phase 4
- Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow up of Patients With Hodgkin's LymphomaRecruitingNCT06761274Not applicable
- Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients with DLBCL Intolerant to ChemotherapyRecruitingNCT06758037Phase 2
- Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular LymphomaNot yet recruitingNCT06757894Phase 2
- A Clinical Study on the Combination of Mitoxantrone Liposome Injection, Bendamustine, Etoposide, and Cytarabine for Pretreatment of Autologous Hematopoietic Stem Cell Transplantation in Patients with LymphomaNot yet recruitingNCT06757478
- Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell LymphomaNot yet recruitingNCT06757387Phase 1/2
- Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with HemoblastosisRecruitingNCT06756152Phase 2/3
- PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell LymphomaRecruitingNCT06755775
- Dynamic CtDNA-guided Targeted Therapy in DLBCLNot yet recruitingNCT06748521Phase 2
- The Value of Artificial Intelligence-based 18F-FDG PET/CT in Diferential Diagnosis, Efficacy Prediction and Prognosis Prediction of T-NK Cell Lymphoma: a Clinical StudyNot yet recruitingNCT06747299
- Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBLRecruitingNCT06742502Phase 2
- VHAG in Treating R/R T-ALL/LBLRecruitingNCT06742463Phase 2
- Allo-HSCT vs ASCT in Adult T-LBLNot yet recruitingNCT06741813Not applicable
- Golidocitinib Plus CHOP in Newly Diagnosed PTCLRecruitingNCT06739265Phase 1/2
- Metabolic Insights: the Impact of F-18 FDG PET/CT in Adult LymphomaNot yet recruitingNCT06737835
- NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSLRecruitingNCT06737250Phase 2
- A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin LymphomaRecruitingNCT06734871Phase 1
- The Microbiome in Blood Cancer and HLHNot yet recruitingNCT06734624
- Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)RecruitingNCT06733051Phase 2
- A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin LymphomaRecruitingNCT06725524Phase 1
- An Extension Study to Evaluate the Safety and Efficacy of an Anti-CD19 CAR-T Product in Patients with B-cell Lymphoproliferative DisordersNot yet recruitingNCT06721598
- Development of Prognostic Models for Response and Toxicity to CAR-T Cell Therapy in Patients with Relapsed/refractory Non Hodgkin's Lymphoma.Not yet recruitingNCT06720701
- Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)Not yet recruitingNCT06712173Phase 1
- Venetoclax and Decitabine in R/R T-ALLRecruitingNCT06712121Phase 2
- Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular LymphomaRecruitingNCT06704555Phase 2
- To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell LymphomaNot yet recruitingNCT06702605Phase 2
- Go-CHOP in de Novo Intestinal T-cell Lymphoma PatientsNot yet recruitingNCT06701344Phase 2
- Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II TrialRecruitingNCT06700798Phase 2
- To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)RecruitingNCT06698484Phase 2
- A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1RecruitingNCT06698003Phase 2
- An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's LymphomaRecruitingNCT06693973Early Phase 1
- ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCLRecruitingNCT06693830Not applicable
- A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell LymphomaRecruitingNCT06683885Phase 1/2
- A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic CancerRecruitingNCT06678659Phase 1/2
- RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DELRecruitingNCT06674096Phase 2
- Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell LymphomaNot yet recruitingNCT06671717Not applicable
- Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial RemissionNot yet recruitingNCT06669143Phase 2
- Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma PatientsNot yet recruitingNCT06665737Phase 4
- Exercise During Chemotherapy Treatment As Adjuvant Program in Patients with Lymphoma: EDONOLA Study.RecruitingNCT06660446Not applicable
- The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter StudyNot yet recruitingNCT06656234
- A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell LymphomaNot yet recruitingNCT06656221Phase 2
- Mechanism Investigation of R-CHOP Regimen or Tucidinostat Plus R-CHOP (CR-CHOP) Regimen in the Treatment of BCL2/MYC Protein Double Expressor LymphomaNot yet recruitingNCT06652152
- Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC PositiveNot yet recruitingNCT06652139Phase 2
- CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic TumorsNot yet recruitingNCT06647329Phase 1
- High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ)Not yet recruitingNCT06646211Phase 2
- Feasibility of Intermittent Fasting During ChemotherapyRecruitingNCT06645093Not applicable
- Exercise as an Immune Adjuvant for Allogeneic Cell TherapiesRecruitingNCT06643221Early Phase 1
- A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin LymphomaRecruitingNCT06642792Phase 1/2
- Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphomaRecruitingNCT06633341Early Phase 1
- One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHLRecruitingNCT06618313Not applicable
- A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid TumorRecruitingNCT06615193Phase 1
- Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell LymphomaRecruitingNCT06609304Phase 4
- MOLyF : Bone Marrow and Follicular LymphomaRecruitingNCT06608147Not applicable
- BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma.RecruitingNCT06598722Phase 2
- Linperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL)RecruitingNCT06592170Phase 1/2
- Flow Cytometry for the Study of T-Cell Populations in Hemophagocytic Lymphohistiocytosis Associated With LymphomasRecruitingNCT06585124
- A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCLNot yet recruitingNCT06573645Phase 3
- Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCLNot yet recruitingNCT06573151Phase 2
- Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCLNot yet recruitingNCT06573138Phase 2
- A Real-World Study on Extranodal LymphomaNot yet recruitingNCT06573099
- CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic FactorsNot yet recruitingNCT06567366Phase 2
- Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone LymphomaRecruitingNCT06566807Phase 2
- A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell LymphomaRecruitingNCT06566586Phase 2
- Epco, Zanu, Ritux for R/R FL or MZLRecruitingNCT06563596Phase 2
- A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone LymphomaRecruitingNCT06563505Phase 2
- MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin LymphomaNot yet recruitingNCT06557330Phase 2
- A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingNCT06554600Phase 2
- Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular LymphomaRecruitingNCT06553352Phase 2
- Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation SequencingRecruitingNCT06550427
- Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)Not yet recruitingNCT06549335Phase 2
- Cellular Immunotherapy for Relapsed or Refractory Lymphoma Data CollectionRecruitingNCT06541327
- Precise Oncology Interventions in Nutrition and Training (OnPoint)RecruitingNCT06534918Not applicable
- Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)RecruitingNCT06534463
- Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)RecruitingNCT06533579Phase 1/2
- Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCLRecruitingNCT06530511Phase 2
- A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell MalignanciesRecruitingNCT06528301Phase 1
- Molecular Mechanisms in Malignant Lymphoma- Predict (MMML Predict)RecruitingNCT06526065
- A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) PhenotypeRecruitingNCT06522737Phase 3
- The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell LymphomaRecruitingNCT06522555Phase 3
- A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)RecruitingNCT06520098Phase 2
- An Exploratory Clinical Study Evaluating the Safety and Efficacy of Intravenous Anti-CD20/CD30-CAR-T Cell Infusion in Relapsed/Refractory Lymphoma Patients.Not yet recruitingNCT06519344Early Phase 1